Trastuzumab Emtansine Delays and Overcomes Resistance to the Third-Generation EGFR-TKI Osimertinib in NSCLC EGFR Mutated Cell Lines
Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/s13046-017-0653-7
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2017
Authors
Publisher
Springer Science and Business Media LLC